Summary
HLA-typing, gene analysis, anti-islet cell antibody testing and metabolic studies can identify people at high risk for developing Type 1 (insulin-dependent) diabetes mellitus prior to the onset of clinical disease. The positive predictive value of these tests is high in first degree relatives of patients with Type 1 diabetes, but six times less so in the general population, where disease incidence is much lower but where 90% of new cases occur. Multiple testing improves sensitivity but decreases specificity. Intervention strategies are being designed with the aim of delaying or preventing progression to clinical disease. The more invasive the intervention, the greater is the specificity required. The practical and ethical implications of identifying high risk of diabetes in healthy individuals are complex and require further research, but some lessons can be learned from the experience of other disease prediction programmes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lappe M, Gustafson J, Robbin R (1972) Ethical and social issues in screening for genetic disease. N Engl J Med 285: 1129–1132
Rothstein MA (1989) Medical screening and the employee health cost crisis. The Bureau of National Affairs, Washington, DC
Tarn AC, Smith CP, Spencer KM, Bottazzo GF, Gale EAM (1987) Type 1 (insulin-dependent) diabetes: a disease of slow clinical onset? Br Med J 294: 342–345
Gorsuch AN, Spencer KM, Lister J et al. (1981) The natural history of type 1 (insulin-dependent) diabetes mellitus: evidence of a long pro-diabetic prodrome. Lancet II: 1363–1365
Chase HP, Voss MA, Butler-Simon N, Hoops S, O'Brien D, Dobersen MJ (1987) Diagnosis of pro-type 1 diabetes. J Ped 111: 807–812
Vardi P, Crisa L, Jackson RA (1991) Predictive value of intravenous glucose tolerance test insulin secretion less than or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 34: 93–102
Dorman JS, Trucco M (1989) How much does HLA-DQ phenotype contribute to the incidence of type 1 diabetes in Allegheny County, PA? Diabetes 38 [Suppl 2]: 34A
Faustman D, Eisenbarth GS, Daley J, Breutmeyer J (1989) Abnormal T-lymphocyte subsets in type 1 diabetes. Diabetes 38: 1462–1468
Bonifacio E., Bingley PJ, Dean BM, Shattock M, Dunger D, Gale EAM (1990) Quantification of islet cell antibodies and prediction of insulin-dependent diabetes. Lancet 335: 147–149
Riley WJ, Maclaren NK, Krischer J et al. (1990) A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. New Engl J Med 323: 1167–1172
Colman PG, Eisenbarth GS (1988) Immunology of type 1 diabe-tes. In: Alberti KGMM, Krall LP (eds) The diabetes annual/4. Elsevier, Amsterdam, pp 17–45
Bingley PJ, Shattock M, Chusney G et al. (1991) Unexpectedly high prevalence of islet cell antibodies in healthy children aged 8–13. Diabetic Med 8 [Suppl 1]: A3
Pauker SG, Kassirer JP (1987) Decision analysis. N Engl J Med 316: 250–258
Childs B, Gordis F, Kaback MM, Kazazian HG (1976) Tay-Sachs screening: motives for participating and knowledge of genetics and probability. Am J Hum Genet 28: 537–549
Fletcher JC (1984) Ethical and social aspects of risk predictions. Clin Genet 25: 25–32
Motulsky G (1989) Societal problems in human and medical genetics. Genome 31: 870–875
Beutler E, Boggs DR, Heller P et al. (1971) Hazards of indiscriminate screening for sickling. N Engl J Med 285: 1485–1486
Jenkins JB, Conneally PM (1989) The paradigm of Huntington's disease. Am J Hum Genet 45: 169–175
Markel DS, Young AB, Penney JB (1987) At-risk persons' attitudes toward presymptomatic and prenatal testing of Huntington's disease in Michigan. Am J Med Genet 26: 295–305
Meissen GJ, Berchek RL (1987) Intended use of predictive testing by those at risk for Huntington's disease. Am J Med Genet 26: 283–293
Quaid KA, Brandt J, Faden RR, Folstein SE (1989) Knowledge, attitude, and the decision to be tested for Huntington's disease. Clin Genet 36: 431–438
Craufurd D, Dodge A, Kerzin-Storrar L, Harris R (1989) Uptake of presymptomatic predictive testing for Huntington's disease. Lancet II: 603–605
Shaw MW (1987) Testing for the Huntington gene: a right not to know, a right to know, or a duty to know. Am J Med Genet 26: 243–246
Wilfond BS, Fost N (1990) The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA 263: 2777–2783
Roberts L (1990) To test or not to test. Science 247: 17–19
Caskey CT, Kaback MM, Beaudet AL (1990) The American Society of Human Genetics statement on cystic fibrosis. Am J Hum Genet 46: 393
Pauker SG, Pauker SP (1987) Prescriptive models to support decision making in genetics. Birth Defects 23: 279–296
Fletcher JC (1984) Ethical and social aspects of risk predictions. Clin Genet 25: 25–32
Motulsky AG (1989) Societal problems in human and medical genetics. Genome 31: 870–875
McNeil BJ, Weichselbaum R, Pauker SG (1981) Speech and survival: tradeoffs between quality and quantity of life in laryngeal cancer. N Engl J Med 305: 982–987
Kodish E, Lantos J, Stocking C, Singer PA, Siegler M, Johnson FL (1991) Bone marrow transplantation for sickle cell disease: a study of parents' decisions. N Engl J Med 325: 1349–1353
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Siegler, M., Amiel, S. & Lantos, J. Scientific and ethical consequences of disease prediction. Diabetologia 35 (Suppl 2), S60–S68 (1992). https://doi.org/10.1007/BF00586280
Issue Date:
DOI: https://doi.org/10.1007/BF00586280